NFE2L2 and cardiomyopathy: TQ treatment (50 mg/kg for 12 weeks, orally) in STZ-treated rats prevented cardiomyopathy by reducing plasma and heart tissue MDA levels but increasing SOD activity with the possible mechanism of increasing Nrf2 expression (52).